Clinical trials: High-Risk Cancer, open to volunteers
Melanoma (Skin), Skin Cancer
High-Intensity Exercise and High-Fiber Diet for Immunotherapy Outcomes in Melanoma Patients: The DUO Trial
The purpose of this study is to determine whether high-intensity exercise and high-fiber diet are feasible and improve various health outcomes among participants with advanced melanoma receiving immunotherapy.
- Conditions
- Melanoma (Skin), Skin Cancer, Advanced Melanoma
- Trial name
- NCT06298734
- Testing
- Exercise Program, Diet Program
- Where
- 2 sites in United States
- Volunteers
- 40 people
- Sponsor
- Fred Hutchinson Cancer Center
Cancer
Advanced Proton Therapy Approaches: a Multicenter High-quality Data Registry
The aim of the present registry is to prospectively collect data on patients treated with protontherapy in order to improve knowledge on indication, feasibility, and clinical results of hypofractionated schedules applied in the…
- Trial name
- NCT05860361
- Where
- Italy
- Volunteers
- 2,000 people
- Sponsor
- European Institute of Oncology
Colon Cancer
A Phase II Study of Tislelizumab as Adjuvant Therapy for Patients With Stage Ⅱ and Stage Ⅲ Colon Cancer and dMMR/MSI.
10%-15% of early-stage colon cancers harbour either deficient mismatch repair (dMMR), microsatellite instability high (MSI-H) is characterised by high tumour mutational burden and increased lymphocytic infiltrate.
- Trial name
- NCT05231850
- Testing
- Tislelizumab
- Volunteers
- 70 people
- Sponsor
- The First Affiliated Hospital of Zhengzhou University
High Grade Glioma, Glioblastoma
Metronomic Temozolomide With Dexbrompheniramine for Recurrent High-Grade Glioma/Glioblastoma
The goal of this clinical trial is to: 1) evaluate the safety, tolerability, and recommended dose of dexbrompheniramine when combined with metronomic temozolomide for adults with recurrent high-grade glioma who have been…
- Conditions
- High Grade Glioma, Glioblastoma, Gliosarcoma
- Trial name
- NCT07859059
- Testing
- Dexbrompheniramine, Temozolomide
- Where
- United States
- Volunteers
- 41 people
- Sponsor
- University of Nebraska
High-risk Muscle Invasive Urothelial Carcinoma
An Open-label Study to Investigate the Efficacy and Safety of Dato-DXd + Rilvegostomig vs SoC in Adult Participants With High-risk MIUC
Purpose: to assess efficacy and safety of Dato-DXd + rilvegostomig as adjuvant therapy versus SoC in MIUC participants with high-risk residual disease after radical resection.
- Trial name
- TU-04 (NCT07720284)
- Testing
- Dato-DXd, Rilvegostomig, Durvalumab
- Where
- 160 sites in United States, Australia and 14 more
- Volunteers
- 915 people
- Sponsor
- AstraZeneca
Rectal Cancer, Rectal Adenocarcinoma
SCARLET - Italian proSpeCtionAl obseRvationaL multicEntre Study on Treatment for recTal pT1 Cancer
The purpose of this prospective, observational, multicenter study is to evaluate the impact of adjuvant radiotherapy or chemoradiotherapy on disease-free survival (DFS) in patients with pathological T1 (pT1) rectal cancer…
- Conditions
- Rectal Cancer, Rectal Adenocarcinoma, Rectal Cancer Patients, Rectal Cancer, Radiotherapy
- Trial name
- SCARLET (NCT07695519)
- Where
- Italy
- Volunteers
- 196 people
- Sponsor
- Fondazione Policlinico Universitario Agostino Gemelli IRCCS
Glioblastoma
Study of Liposomal Curcumin in Combination With RT and TMZ in Patients With Newly Diagnosed High-Grade Gliomas
The objective of this study is to assess the tolerability, safety, and efficacy of Liposomal Curcumin (LC) in combination with radiotherapy (RT) and Temozolomide (TMZ) in patients with newly diagnosed High-Grade Gliomas (HGG).
- Trial name
- NCT05768919
- Testing
- Treatment Period 1, Treatment Period 2, Treatment Period 3
- Where
- 2 sites in United States
- Volunteers
- 30 people
- Sponsor
- SignPath Pharma, Inc.
Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8
Testing Whether Hormone Therapy With Ribociclib is as Effective as Chemotherapy Followed by Hormone Therapy With Ribociclib for the Treatment of High Anatomic Stage Breast Cancer With Low Recurrence Risk, The RxFINE-Low Trial
This phase III trial compares standard of care hormone therapy plus ribociclib to chemotherapy followed by hormone therapy plus ribociclib for the treatment of patients with high anatomic stage breast cancer with low risk of the…
- Conditions
- Anatomic Stage II Breast Cancer AJCC v8, Anatomic Stage IIIA Breast Cancer AJCC v8, Anatomic Stage IIIC Breast Cancer AJCC v8, Estrogen Receptor-Positive Breast Carcinoma
- Trial name
- NCT07391774
- Testing
- Anastrozole, Biospecimen Collection, Bone Scan
- Where
- 243 sites in United States, Puerto Rico
- Volunteers
- 1,978 people
- Sponsor
- National Cancer Institute (NCI)
Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia
The Patient Cohort of the National Center for Precision Medicine in Leukemia
If for years the treatment strategy of leukemia and related disorders (LRDs, including acute leukemias and predisposition syndromes) has been based solely on whether the patient could receive or not intensive chemotherapy and…
- Conditions
- Acute Myeloid Leukemia, Acute Lymphoblastic Leukemia, High-risk Myelodysplastic Syndrome, Secondary Myelofibrosis in Myeloproliferative Disease
- Trial name
- eTHEMA (NCT05326919)
- Testing
- Biobanking
- Where
- 3 sites in France
- Volunteers
- 3,000 people
- Sponsor
- Assistance Publique - Hôpitaux de Paris
Diffuse Large B Cell Lymphoma
CNS-Relapse Prevention in High-Risk Diffuse Large B-cell Lymphoma With Thiotepa-based Autologous Stem Cell Transplant
A serious consequence of systemic diffuse large B-cell lymphoma (DLBCL) is secondary central nervous system (CNS) relapse, which occurs in approximately 5% of all patients.
- Trial name
- CNS-PHLAT (NCT06687772)
- Testing
- Thiotepa, Carmustine, Autologous Stem Cell Transplant
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- Washington University School of Medicine
Bladder Cancer, Liquid Biopsy
Urinary Tumor DNA-Guided Systemic Immunotherapy for Unresectable Very-High-Risk Non-Muscle-Invasive Bladder Cancer
This study evaluates whether urinary tumor DNA (utDNA) testing, together with clinical, pathologic, and radiographic assessment, can help guide treatment discontinuation and active surveillance in patients with unresectable…
- Conditions
- Bladder Cancer, Liquid Biopsy, Immunotherapy
- Trial name
- NCT07475403
- Testing
- Systemic immunotherapy
- Where
- 3 sites in China
- Volunteers
- 53 people
- Sponsor
- Tianjin Medical University Second Hospital
Breast Cancer
SAHARA-04 : Adaptive Radiotherapy in Hypersensitive Patients and High Locoregional Risk Breast Cancer With ETHOS Technology
Prospective, open-label, bi-center study, assessing the clinical outcomes of adaptive breast radiotherapy with ETHOS in hypersensitive patients.
- Trial name
- SAHARA-04 (NCT06053086)
- Testing
- Treatment ETHOS radiotherapy, Conventional IMRT
- Where
- France
- Volunteers
- 500 people
- Sponsor
- Institut du Cancer de Montpellier - Val d'Aurelle
Cervical Intraepithelial Neoplasia, Squamous Intraepithelial Lesions of the Cervix
Conservative Management of HSIL in Patients With Future Pregnancy Aspiration
Conservative management of high-grade squamous intraepithelial lesions (HSILs) seems safe and justified in young women (<30 years), but evidence is insufficient on whether it is also advisable for older women.
- Conditions
- Cervical Intraepithelial Neoplasia, Squamous Intraepithelial Lesions of the Cervix, Uterine Cervical Dysplasia
- Trial name
- NCT04783805
- Testing
- Conservative management with regular follow-up, Conization
- Where
- Spain
- Volunteers
- 200 people
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
Breast Cancer
High-Resolution Lower Dose Dedicated Breast Computed Tomography (CT)
This study is being performed to find out if a new kind of breast imaging (called dedicated breast CT or BCT) can help doctors to see the small structures in breast tissue more clearly.
- Trial name
- LowerDoseBCT (NCT03954431)
- Testing
- Dedicated breast CT(BCT)
- Where
- United States
- Volunteers
- 600 people, healthy volunteers welcome
- Sponsor
- University of Arizona
Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome
Edetate Calcium Disodium or Succimer in Treating Patients With Acute Myeloid Leukemia or Myelodysplastic Syndrome Undergoing Chemotherapy
This phase I trial studies the side effects and best dose of edetate calcium disodium or succimer in treating patients with acute myeloid leukemia or myelodysplastic syndrome undergoing chemotherapy.
- Conditions
- Acute Myeloid Leukemia, Acute Myeloid Leukemia Arising From Previous Myelodysplastic Syndrome, Blast Phase Chronic Myelogenous Leukemia, BCR-ABL1 Positive, Chronic Myelogenous Leukemia, BCR-ABL1 Positive
- Trial name
- NCT03630991
- Testing
- Edetate Calcium Disodium, Multivitamin, Succimer
- Where
- United States
- Volunteers
- 58 people
- Sponsor
- M.D. Anderson Cancer Center
High Grade Glioma, Astrocytoma
Study of Olutasidenib and Temozolomide in HGG
The goal of this study is to determine the efficacy of the study drug olutasidenib to treat newly diagnosed pediatric and young adult patients with a high-grade glioma (HGG) harboring an IDH1 mutation.
- Conditions
- High Grade Glioma, Astrocytoma, Astrocytoma, Grade III, Astrocytoma, Grade IV
- Trial name
- NCT06161974
- Testing
- Olutasidenib + TMZ
- Where
- 20 sites in United States, Australia and 5 more
- Volunteers
- 60 people
- Sponsor
- Rigel Pharmaceuticals
High Risk Prostate Cancer
PRospective Observational Study of STereotactic Body rAdiation Therapy With Androgen Deprivation Therapy for Organ-confined High-risk Prostate Cancer: the PROSTAR Trial
Prostate Cancer (PCa) is the second most common malignancy and the 5th common cause of cancer-related mortality in men worldwide.
- Trial name
- PROSTAR (NCT06949254)
- Where
- 3 sites in Italy
- Volunteers
- 49 people
- Sponsor
- Istituto Clinico Humanitas
Breast Cancer, Chemotherapy Effect
Efficacy of Supplement Adjuvant Capecitabine in HR+/HER2- Breast Cancer Patients With High Risks
According to the latest data from the World Health Organization's International Agency for Research on Cancer (IARC) for 2020, breast cancer has been the most prevalent cancer with 2.26 million new cases.
- Trial name
- NCT05212454
- Testing
- Capecitabine
- Where
- China
- Volunteers
- 400 people
- Sponsor
- Second Affiliated Hospital, Zhejiang University, School of Medicine
Colorectal Carcinoma
PACE: PD-1 Antibody For dMMR/MSI-H Stage III Colorectal Cancer
In this open-label phase III study, patients with local advanced colon cancer (TanyN+ ,M0, dMMR/MSI-H, at least 10cm from the anus verge)will be scheduled to Group A: receive anti-PD-1 antibody alone (8 cycles, 200mg iv drip Q3W)…
- Trial name
- NCT05236972
- Testing
- Sintilimab, Oxaliplatin, capecitabine
- Where
- China
- Volunteers
- 323 people
- Sponsor
- Sun Yat-sen University
Colorectal Neoplasms, Fluorescence
Fluorescence Laparoscopic Navigation for Rectal Cancer and Sigmoid Colon Cancer
To explore the short-term and long-term outcomes of fluorescence laparoscopic navigation D2 lymph node dissection for colorectal cancer surgery by comparing it with D3 lymph node dissection.
- Conditions
- Colorectal Neoplasms, Fluorescence, Lymph Node Excision
- Trial name
- FLORA-01 (NCT05730595)
- Testing
- lymph node dissection
- Where
- 19 sites in China
- Volunteers
- 550 people
- Sponsor
- Cancer Institute and Hospital, Chinese Academy of Medical Sciences
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.